NASDAQ · DRTSW

Alpha Tau Medical Ltd.

$2.97 -$0.21 (-6.60%) 1D Market open

Key Metrics

$206.05M
Market cap
P/E · TTM
Revenue · TTM
−$42.63M
Net income
EPS · TTM $-0.61
Dividend yield
Free cash flow −$32.76M
Beta · 1Y 2.70
EBITDA · TTM −$41.27M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    The stock moved +51.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11
  • Apr 30
    The stock moved +43.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 30
  • Apr 9
    From its Feb 25 high, the share price fell 47%.

    Peak close $1.50 on Feb 25; trough close $0.80 on Apr 9. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -47%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$138.17M
Shares outstanding
52-wk range$0.20 – $4.28
Avg volume · 20D43.3K
Net cash $67.88M
Book value / share$1.11
ExchangeNASDAQ
About Alpha Tau Medical Ltd.
IPO dateMar 8, 2022
Employees121

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -61.0% · -462.3%

Financial Health

Current ratio7.45
Quick ratio
Debt / equity0.07
Debt / EBITDA -0.13
Net cash $67.88M
Working capital$67.79M

Cash Flow · TTM

Operating CF −$26.68M
Capex −$6.08M
Free cash flow −$32.76M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings